Paris, May 18 (Ians) A Covid-19 vaccine developed by pharmaceutical giants Sanofi and Glaxo Smith Kline (Gsk) has shown strong rates of neutralising antibody responses against the infectious Coronavirus disease in the Phase-ii trial.
The Phase-ii trial, which involved 722 adult volunteers from the US and Honduras between 18 to 95 years old, did not raise any safety concerns and also produced a strong immune response across all age groups.
It showed 95 per cent to 100 per cent seroconversion following a second injection, while a single jab produced high neutralising antibody levels among people with prior Sars-CoV-2 infection. This suggested the vaccine's strong potential for development as a booster shot.
The vaccine also elicited strong neutralising antibody levels that were comparable to those generated by natural infection. The higher levels observed in people between 18 to 59 years old.
"Our Phase 2 data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis,...
The Phase-ii trial, which involved 722 adult volunteers from the US and Honduras between 18 to 95 years old, did not raise any safety concerns and also produced a strong immune response across all age groups.
It showed 95 per cent to 100 per cent seroconversion following a second injection, while a single jab produced high neutralising antibody levels among people with prior Sars-CoV-2 infection. This suggested the vaccine's strong potential for development as a booster shot.
The vaccine also elicited strong neutralising antibody levels that were comparable to those generated by natural infection. The higher levels observed in people between 18 to 59 years old.
"Our Phase 2 data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis,...
- 5/18/2021
- by Glamsham Bureau
- GlamSham
IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news articles, Tweets, and blog posts do not represent IMDb's opinions nor can we guarantee that the reporting therein is completely factual. Please visit the source responsible for the item in question to report any concerns you may have regarding content or accuracy.